Showing results (181-190 of 237) with videos related to

Sort By:
Pageof 24
Diabetic Medicine : a Journal of the British Diabetic Association|September 1, 1990
A preliminary multicentre study of the treatment of recently diagnosed type 1 diabetes by combination nicotinamide-cyclosporin therapyB Vialettes, R Picq, M du Rostu, et al.
Diabetes & Metabolism|June 27, 2006
C-peptide replacement improves weight gain and renal function in diabetic ratsL Rebsomen, S Pitel, F Boubred, et al.
European Journal of Clinical Pharmacology|January 1, 1987
Correction by pentoxifylline of the abnormal fluorescence polarization of erythrocyte membranes from diabetic patientsD Rahmani-Jourdheuil, I Juhan-Vague, C Roul, et al.
Annales De Chirurgie|January 1, 1991
[Pancreatic conservation after autotransplantation in dogs. Value of histologic surface analysis]P Orsoni, G Houvenaeghel, G Monges, et al.
Diabetes & Metabolism|December 15, 2010
Access of children and adolescents with type 1 diabetes to insulin pump therapy has greatly increased in France since 2001V Sulmont, V Lassmann-Vague, B Guerci, et al.
Metabolism: Clinical and Experimental|March 1, 1986
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjectsP Vague, I Juhan-Vague, M F Aillaud, et al.
Diabetologia|July 1, 1986
Correction by insulin added in vitro of abnormal membrane fluidity of the erythrocytes from type 1 (insulin-dependent) diabetic patientsI Juhan-Vague, D Rahmani-Jourdheuil, Z Mishal, et al.
Diabete & Metabolisme|July 1, 1987
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1I Juhan-Vague, P Vague, M C Alessi, et al.
Diabetes, Obesity & Metabolism|January 12, 2005
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulinI De Leeuw, P Vague, J-L Selam, et al.
Acta Endocrinologica|July 1, 1993
Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignanciesB Vialettes, M A Guillerand, P Viens, et al.
Pageof 24